CRACR2A

Across TCGA pan-cancer cohorts, CRACR2A RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of CRACR2A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CRACR2A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CRACR2A is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

KIRC, KIRP, and LUAD are the cancer types where CRACR2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CRACR2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.951	<.001	12	view →
KIRP	Male	All	+0.679	<.001	7	view →
LUAD	All	All	+0.373	<.001	6	view →
CHOL	All	All	+1.511	<.001	5	view →
LIHC	All	All	+0.244	.005	5	view →
BRCA	Female	All	−0.323	.013	4	view →
STAD	Male	All	+0.505	.012	2	view →
LUSC	All	All	+0.295	.004	2	view →
ESCA	Female	All	+1.580	.024	1	view →
THCA	All	II,III,IV	+0.356	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

CRACR2A–KIRC

Open the KIRC breakdown →